Development of a scoring system to screen for BRCA1/2 mutations.

Area of Science:

• Medical Genetics
• Oncology
• Clinical Decision Support

Background:

• Genetic testing for BRCA1 and BRCA2 mutations is crucial for cancer risk assessment.
• High costs of genetic testing persist, necessitating efficient selection strategies.
• Existing computer-based models for predicting mutation likelihood can be complex and time-consuming.

Purpose of the Study:

• To validate and describe the Manchester scoring system for selecting patients for BRCA1/BRCA2 genetic testing.
• To compare the effectiveness of the Manchester scoring system against other predictive models.
• To assess the utility of the Manchester scoring system in Western populations.

Main Methods:

• Development and validation of the Manchester scoring system, a clinical tool.
• Comparison of the Manchester scoring system with established computer-based predictive models.
• Evaluation of the scoring system's performance at 10% and 20% mutation detection thresholds.

Main Results:

• The Manchester scoring system effectively discriminates mutation likelihood at standard testing thresholds (10-20%).
• The system demonstrates comparable performance to more complex computational models.
• The scoring system is validated for use in Western populations.

Conclusions:

• The Manchester scoring system provides a practical and effective method for guiding BRCA1/BRCA2 genetic testing decisions.
• The system offers a valuable alternative to complex models in busy clinical settings.
• Consideration for population-specific adjustments (e.g., lower thresholds for founder or low-incidence populations) is recommended.